Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis.
Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. · 2020
Read Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. by Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7836017.txt.
Introduction
Poznyak and co-authors overview oxidized LDL and its effect on heart and vessel health. Heart disease leads world death counts. Atherosclerosis, the artery-hardening disease, sits behind much of it. Inflammation and fat handling both drive it.
For decades, oxidized LDL was cast as the main harmful fat form. Newer work paints a wider picture. LDL particles pass through many changes in blood and artery walls. Oxidation may be the last step, not the first. Oxidized LDL can stir inflammation through macrophages. Oddly, it can also calm inflammation in some settings. The authors sort these mixed findings by disease stage. The topic stays ripe for more study.
Catalog record
| CREATOR | Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis By Anastasia V Poznyak, Nikita G Nikiforov, Alexander M Markin, Dmitry A Kashirskikh, Veronika A Myasoedova, Elena V Gerasimova, Alexander N Orekhov Published in: Frontiers in Pharmacology DOI: 10.3389/fphar.2020.613780 ABSTRACT Abstract Cardiovascular pathologies maintain the leading position in mortality worldwide. Atherosclerosis is a chronic disease that can result in a variety of serious complications, such as myocardial infarction, stroke, and cardiovascular disease. Inflammation and lipid metabolism alterations play a crucial role in atherogenesis, but the details of relationships and causality of these fundamental processes remain not clear. The oxidation of LDL was considered the main atherogenic modification of LDL within the vascular wall for decades. However, recent investigations provided a growing body of evidence in support of the multiple LDL modification theory. It suggests that LDL particles undergo numerous modifications that change their size, density, and chemical properties within the blood flow and vascular wall. Oxidation is the last stage in this cascade resulting in the atherogenic properties. Moreover, recent investigations have discovered that oxLDL may have both anti-inflammatory and pro-inflammatory properties. Oxidized LDL can trigger inflammation through the activation of macrophages and other cells. After all, oxidized LDL is still a promising object for further investigations that have the potential to clarify the unknown parts of the atherogenic process. In this review, we discuss the role of oxLDL in atherosclerosis development on different levels. Keywords: oxLDL, atherosclerosis, cardiovascular disease, low-density lipoprotein, oxidative stress OXIDATIVE MODIFICATION HYPOTHESIS Cardiovascular disease (CVD) is one of the leading causes of premature death and disability in Europe. According to the World Health Organization (WHO), about 75% of all deaths from CVD can be prevented by following a healthy lifestyle. A healthy lifestyle includes smoking cessation, a healthy diet, and sufficient physical activity (Benjamin et al., 2019). Brown and Goldstein were the first to postulate that LDL has to undergo some structural changes to achieve atherogenic properties (Brown and Goldstein, 1983). They also figured out that circulating LDL uptake by macrophages is not fast enough to load the cell with cholesterol, which is necessary for the foam cell formation. Moreover, patients totally deficient for the native LDL receptor are still able to store large amounts of cholesterol in their macrophages. Consequently, they suggested that the classic LDL receptor is not involved in the uptake of modified LDL. Goldstein et al. also found the acetyl LDL receptor, i.e., responsible for the modified LDL uptake (Goldstein et al., 1979). Later, this receptor was cloned in Krieger’s laboratory and called scavenger receptor A (Kodama et al., 1988). Several more scavenger receptors were identified. Also, several different LDL modifications that make particles recognizable for scavenger receptors of macrophages are known. Among such modifications, enzymatic modifications are complexing with immunoglobulins and oxidation (Steinberg and Witztum, 1990). Oxidative stress manifests itself in excessive ROS generation and oxidation of LDL particles. The emergence of oxLDL is crucial for the progression of CVD linked to atherosclerosis. The main factor underlying oxidative stress is a disbalance between radical production (reactive oxygen and/or nitrogen species formation) and radical scavenging systems (the antioxidant defense system) (Leopold and Loscalzo, 2008). Also, hypertension, insulin resistance, diabetes mellitus, hypercholesterolemia, obesity, dyslipidemia, a high level of C-reactive protein (CRP), immunological disorder, vascular wall inflammation, a genetic predisposition, bacterial infection, stress, alcohol consumption, and smoking were all observed to be risk factors for atherosclerosis development (Holvoet, 2012). OxLDL can trigger the expression of adhesion molecules on the cell surface and thus stimulate the activation of endothelial cells (Obermayer et al., 2018). These adhesion molecules mediate the rolling and adhesion of blood leukocytes, that adhere to the endothelium and then, in response to chemokines, migrate into the intima. As the consequence of the macrophage activation, proinflammatory cytokines are released, ROS are synthesized, and proteolytic enzymes are also produced that contribute to the matrix degradation. This leads to plaque destabilization (Chen and Khismatullin, 2015) Table 1. [Table: The effect of oxLDL on key mechanisms involved in atherogenesis.] Apart from the scavenger receptors, as SR-A, SR-BI, and CD36, oxLDL also binds to lectin-like oxidized low-density lipoprotein receptor-1 (Zani et al., 2015). LOX-1 consists of a short N-terminal cytoplasmic domain, a transmembrane domain, a neck region, and an extracellular C-type lectin-like extracellular domain. Together they form a type II integral membrane glycoprotein, which was first described as the crucial oxLDL receptor of EC cells (Pirillo et al., 2013). Later, the same receptor was shown on the surface of smooth muscle cells and macrophages. Contribution of LOX-1 to atherosclerosis is briefly summarized in Figure 1. [Figure: OxLDL binding to LOX-1 triggers various processes in cells of different types. It enhance OxLDL uptake in both macrophages and VSMCs, and stimulate foam cell formation. It also contributes to the endothelial activation and induces apoptosis in VSMCs.] Under normal conditions, LOX-1 expression is very low, but it can be enhanced in response to proatherogenic or proinflammatory triggers. The LOX-1 level is upregulated in endothelial cells at the early stages of atherogenesis and in advanced plaques. Also, intimal SMCs and macrophages exhibit enhanced expression of LOX-1 in human carotid atherosclerotic plaques (Kattoor et al., 2019). This is potential evidence of the LOX-1 involvement in foam cell formation and activation of the endothelium. Experiments on mice have shown that LOX-1 can also play an important role in the inflammatory response and lipid deposition in heart vessels (Xu et al., 2013). Overproduction of oxLDL triggers the LOX-1 expression in VSMCs and also triggers apoptosis (Wu et al., 2017). Expression of the proapoptotic protein Bcl-2-associated X protein (Bax) is increased, as well as the expression of the anti-apoptotic protein Bcl2 in response to excessive oxLDL formation (Liu et al., 2005;Toledo-Ibelles and Mas-Oliva, 2018). LOX-1 mediates this effect, and, accordingly, anti-LOX-1 antibodies inhibit the ox-LDL-induced apoptosis. All this data, combined with the colocalization of LOX-1 and Bax in human atherosclerotic plaques, particularly in the rupture-prone shoulder region, provide shreds of evidence of the potential involvement of LOX-1 in the atherosclerotic plaque destabilization (Kataoka et al., 2001). Lysophosphatidylcholine (LPC) treatment can also increase LOX-1 expression in SMCs. This, subsequently, leads to an increase in oxLDL uptake. Anti-LOX-1 antibodies were shown to inhibit the uptake of oxLDL after the LPC stimulation (Chistiakov et al., 2016). OxLDL affects the NLRP3 inflammasome as well. OxLDL and cholesterol crystal accumulation are important triggers of inflammasome activation, which serves as the link between inflammation and lipid metabolism. OxLDL can activate the NLRP3 inflammasome even without cholesterol crystals. Macrophages uptake oxLDL via CD36, which results in the intracellular nucleation of cholesterol crystals in lysosomes. This process activates inflammasome with the same result as when the cholesterol crystals are phagocytosed (Poznyak et al., 2020b). Oxidative modification has been attracting the attention of researchers for the last two decades. Therefore, it is the most well-investigated LDL modification for now. What is more, antioxidant compounds, including probucol, probucol analogs, vitamin E, coenzyme Q, diphenylphenylenediamine, and butylated hydroxytoluene were investigated in the scope of atherosclerosis and oxLDL in various animal models. Mostly, the results of these investigations were successful (Witztum and Steinberg, 2001). The oxidative modification hypothesis was suggested by Steinberg and Chisolm groups (Hessler et al., 1979; Henriksen et al., 1981; Steinberg